<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981069</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20160597H</org_study_id>
    <nct_id>NCT02981069</nct_id>
  </id_info>
  <brief_title>Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM</brief_title>
  <official_title>Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in Type 2 Diabetes Mellitus (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous&#xD;
      glucose production) and plasma glucose concentration in diabetic subjects. Researchers will&#xD;
      examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and&#xD;
      fall in plasma glucose concentration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine whether the coadministration of exenatide plus dapagliflozin will&#xD;
      prevent the increase in EGP and result in an additive or even synergistic decrease in plasma&#xD;
      glucose concentration compared to each agent alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Endogenous Glucose Production (EGP) for Dapagliflozin only</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EGP for Dapagliflozin plus exenatide (Byetta)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin/exenatide (Byetta)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EGP for Dapagliflozin plus exenatide (Bydureon)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin/exenatide (bydureon)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EGP for Exenatide (Byetta) vs dapagliflozin/exenatide</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following exenatide (byetta) alone versus dapagliflozin/exenatide (byetta)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EGP for dapagliflozin vs placebo</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin alone versus the change in EGP following placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EGP for exenatide (byetta) vs placebo</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin alone, exenatide alone, and dapagliflozin/exenatide versus the change in EGP following placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EGP for dapagliflozin/exenatide vs placebo</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin/exenatide versus the change in EGP following placebo.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Byetta / Bydureon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exenatide:&#xD;
4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Byetta/Bydureon plus Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exenatide:&#xD;
4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS&#xD;
Dapagliflozin:&#xD;
4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group (4 weeks and 12 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>10mg</description>
    <arm_group_label>Byetta/Bydureon plus Dapagliflozin</arm_group_label>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)</description>
    <arm_group_label>Byetta / Bydureon</arm_group_label>
    <arm_group_label>Byetta/Bydureon plus Dapagliflozin</arm_group_label>
    <other_name>Byetta, Bydureon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for Dapagliflozin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. BMI = 25-35 kg/m^2&#xD;
&#xD;
          2. must be drug naïve and/or on a stable dose (more than 3 months) of metformin and/or&#xD;
             sulfonylurea&#xD;
&#xD;
          3. HbA1c &gt;7.0% and &lt;10.0%&#xD;
&#xD;
          4. Other than diabetes, subjects must be in good general health as determined by physical&#xD;
             exam, medical history, blood chemistries, CBC, TSH, T4, EKG and urinanalysis.&#xD;
&#xD;
          5. Only subjects whose body weight has been stable (± 3 lbs) over the preceding three&#xD;
             months and who do not participate in an excessively heavy exercise program will be&#xD;
             included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of significant systemic disease, heart problems including congestive heart&#xD;
             failure, unstable angina or acute myocardial infarction, current infectious liver&#xD;
             disease, acute stroke or transient ischemic attacks, history of pancreatitis,&#xD;
             urosepsis and pyelonephritis, genital mycotic infections, or Type 1 diabetes mellitus&#xD;
&#xD;
          2. Any hepatic diseases in the past (infectious liver disease, viral hepatitis, toxic&#xD;
             hepatic damage, jaundice of unknown etiology) or severe hepatic insufficiency and/or&#xD;
             significant abnormal liver function tests defined as aspartate aminotransferase (AST)&#xD;
             &gt;3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) &gt;3x ULN&#xD;
&#xD;
          3. Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women or ≥1.5 mg/dl for&#xD;
             men, or eGFR &lt;60 mL/min/1.73 m2) or history of unstable or rapidly progressing renal&#xD;
             disease or end stage renal disease.&#xD;
&#xD;
          4. Uncontrolled thyroid disease , Cushing's syndrome, congenital adrenal hyperplasia or&#xD;
             hyperprolactinemia&#xD;
&#xD;
          5. Significantly elevated triglyceride levels (fasting triglyceride &gt; 400 mg/dl),&#xD;
             uncontrolled increased LDL-C&#xD;
&#xD;
          6. Untreated or poorly controlled hypertension (sitting blood pressure &gt; 160/95 mm Hg)&#xD;
&#xD;
          7. Use of anti-obesity drugs or weight loss medications (prescription or OTC) and&#xD;
             medications known to exacerbate glucose tolerance (such as isotretinoin, , GnRH&#xD;
             agonists, glucocorticoids, anabolic steroids, C-19 progestins) stopped for at least 8&#xD;
             weeks. Use of anti-androgens that act peripherally to reduce hirsutism such as 5-alpha&#xD;
             reductase inhibitors (finesteride, spironolactone, flutamide) stopped for at least 4&#xD;
             weeks&#xD;
&#xD;
          8. Prior history of a malignant disease requiring chemotherapy, prior history of bladder&#xD;
             cancer regardless treatment&#xD;
&#xD;
          9. Patients at risk for volume depletion due to co-existing conditions or concomitant&#xD;
             medications, such as loop diuretics should have careful monitoring of their volume&#xD;
             status&#xD;
&#xD;
         10. History of unexplained microscopic or gross hematuria, or microscopic hematuria at&#xD;
             visit 1, confirmed by a follow-up sample at next scheduled visit.&#xD;
&#xD;
         11. Presence of hypersensitivity to dapagliflozin or other SGLT2 inhibitors (e.g.&#xD;
             anaphylaxis, angioedema, exfoliative skin conditions&#xD;
&#xD;
         12. Known hypersensitivity or contraindications to use GLP1 receptor agonists (exenatide,&#xD;
             liraglutide)&#xD;
&#xD;
         13. Use of , thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2&#xD;
             inhibitors stopped for at least 8 weeks.&#xD;
&#xD;
         14. Eating disorders (anorexia, bulimia) or gastrointestinal disorders&#xD;
&#xD;
         15. Suspected pregnancy (documented negative serum β-hCG test), desiring pregnancy in next&#xD;
             6 months, breastfeeding, or known pregnancy in last 2 months&#xD;
&#xD;
         16. Active history of illicit substance abuse or significant intake of alcohol&#xD;
&#xD;
         17. Having a history of bariatric surgery&#xD;
&#xD;
         18. Patient not willing to use two barrier method contraception during study period&#xD;
             (unless sterilized or have an IUD)&#xD;
&#xD;
         19. Debilitating uncontrolled psychiatric disorder such as psychosis or neurological&#xD;
             condition that might confound outcome variables&#xD;
&#xD;
         20. Inability or refusal to comply with protocol&#xD;
&#xD;
         21. Current participation or participation in an experimental drug study in previous three&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugenio Cersosimo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugenio Cersosimo, MD, PhD</last_name>
    <phone>210-358-7200</phone>
    <email>cersosimo@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ralph DeFronzo, MD</last_name>
    <phone>210-567-6691</phone>
    <email>defronzo@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenio Cersosimo, MD</last_name>
      <phone>210-358-7200</phone>
      <email>cersosimo@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ralph A DeFronzo, MD</last_name>
      <phone>210-567-6691</phone>
      <email>defronzo@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eugenio Cersosimo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

